Back to results
US 2024/0254227 A1Published application
Anti-CD300LB Antibodies and Methods of Use Thereof
AssigneeAlector LLC
InventorsSarah Emily Headland, Ilaria Tassi, Chenyu A. Lee, Earl Kim, Adiljan Ibrahim, Marina Roell, Angie Grace Yee
Life of this patent
Estimating the term…
Abstract
The present disclosure is generally directed to antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD300LB polypeptide, e.g., a mammalian CD300LB or human CD300LB, and use of such compositions in preventing, reducing risk, or treating a disease or disorder an individual in need thereof.
Claims42
An isolated antibody that specifically binds to CD300LB, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region (VH) comprises:
- a. an HVR-H1 comprising an amino acid sequence chosen from any one of SEQ ID NOs:36-46;
- b. an HVR-H2 comprising an amino acid sequence chosen from any one of SEQ ID NOs:47-64;
- and
- c. an HVR-H3 comprising an amino acid sequence chosen from any one of SEQ ID NOs:65-79.
1 more element
An isolated antibody that specifically binds to human CD300LB, wherein the antibody comprises a VH comprising HVR-H1, HVR-H2, and HVR-H3 and a VL comprising HVR-L1, HVR-L2, and HVR-L3 of any one of antibodies CD-01, CD-02, CD-03, CD-04, CD-05, CD-06, CD-07, CD-07, CD-09, CD-10, CD-11, CD-12, CD-13, CD-14, CD-15, CD-16, CD-17, and CD-18.
An isolated antibody that specifically binds to human CD300LB, wherein the antibody comprises:
- a. a VH comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:36, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:47, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:65;
- and a VL comprising an HVR-L1 comprising the amino acid sequence of SEQ ID NO:80, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:97, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 112;
- b. a VH comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:37, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:48;
- an HVR-H3 comprising the amino acid sequence of SEQ ID NO:66, an HVR-L1 comprising the amino acid sequence of SEQ ID NO:81;
- and a VL comprising an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 98, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 113;
- c. a VH comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:38, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:49, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:67;
- and a VL comprising an HVR-L1 comprising the amino acid sequence of SEQ ID NO:82, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:99, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 114;
- d. a VH comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:36, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:50, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:68;
- and a VL comprising an HVR-L1 comprising the amino acid sequence of SEQ ID NO:83, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 100, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 112;
- e. a VH comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:39, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:51, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:69;
- and a VL comprising an HVR-L1 comprising the amino acid sequence of SEQ ID NO:84, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:101, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 115;
- f. a VH comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:40, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:52, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:70;
- and a VL comprising an HVR-L1 comprising the amino acid sequence of SEQ ID NO:85, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 102;
- and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 116;
- g. a VH comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:41, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:53, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:71;
- and a VL comprising an HVR-L1 comprising the amino acid sequence of SEQ ID NO:86, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 103, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 117;
- h. a VH comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:42, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:54, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:72;
- and a VL comprising an HVR-L1 comprising the amino acid sequence of SEQ ID NO:87, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 104, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 118;
- i. a VH comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:40, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:55, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:70;
- and a VL comprising an HVR-L1 comprising the amino acid sequence of SEQ ID NO:85, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 102, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 116;
- j. a VH comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:43, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:56, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:73;
- and a VL comprising an HVR-L1 comprising the amino acid sequence of SEQ ID NO:88, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 105, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 119;
- k. a VH comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:44, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:57, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:74;
- and a VL comprising an HVR-L1 comprising the amino acid sequence of SEQ ID NO:89, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 106, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 120;
- l. a VH comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:44, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:58, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:75;
- and a VL comprising an HVR-L1 comprising the amino acid sequence of SEQ ID NO:90, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 107, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:121;
- m. a VH comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:44, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:59, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:75;
- and a VL comprising an HVR-L1 comprising the amino acid sequence of SEQ ID NO:91, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:108, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 122;
- n. a VH comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:45, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:60, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:76;
- and a VL comprising an HVR-L1 comprising the amino acid sequence of SEQ ID NO:92, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 109, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 123;
- o. a VH comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:44, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:61, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:77;
- and a VL comprising an HVR-L1 comprising the amino acid sequence of SEQ ID NO:93, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:110, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:121;
- p. a VH comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:44, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:77;
- and a VL comprising an HVR-L1 comprising the amino acid sequence of SEQ ID NO:94, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:110, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 124;
- q. a VH comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:44, HVR-H2 comprising the amino acid sequence of SEQ ID NO:63, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:78;
- and a VL comprising an HVR-L1 comprising the amino acid sequence of SEQ ID NO:95, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 107, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 125;
- or
- r. a VH comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:46, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:64, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:79;
- and a VL comprising an HVR-L1 comprising the amino acid sequence of SEQ ID NO:96, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:111, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 126.
63 more elements
An isolated antibody that specifically binds to human CD300LB, wherein the antibody comprises:
- a. a VH and VL, wherein the VH comprises the HVR-H1, HVR-H2, and HVR-H3 of the antibody CD-01 (as shown in Table 14) and the VL comprises the HVR-L1, HVR-L2, and HVR-L3 of the antibody CD-01 (as shown in Table 15);
- b. VH and VL, wherein the VH comprises the HVR-H1, HVR-H2, and HVR-H3 of the antibody CD-02 (as shown in Table 14) and the VL comprises the HVR-L1, HVR-L2, and HVR-L3 of the antibody CD-01 (as shown in Table 15);
- c. VH and VL, wherein the VH comprises the HVR-H1, HVR-H2, and HVR-H3 of the antibody CD-03 (as shown in Table 14) and the VL comprises the HVR-L1, HVR-L2, and HVR-L3 of the antibody CD-01 (as shown in Table 15);
- d. VH and VL, wherein the VH comprises the HVR-H1, HVR-H2, and HVR-H3 of the antibody CD-04 (as shown in Table 14) and the VL comprises the HVR-L1, HVR-L2, and HVR-L3 of the antibody CD-01 (as shown in Table 15);
- e. VH and VL, wherein the VH comprises the HVR-H1, HVR-H2, and HVR-H3 of the antibody CD-05 (as shown in Table 14) and the VL comprises the HVR-L1, HVR-L2, and HVR-L3 of the antibody CD-01 (as shown in Table 15);
- f. VH and VL, wherein the VH comprises the HVR-H1, HVR-H2, and HVR-H3 of the antibody CD-06 (as shown in Table 14) and the VL comprises the HVR-L1, HVR-L2, and HVR-L3 of the antibody CD-01 (as shown in Table 15);
- g. VH and VL, wherein the VH comprises the HVR-H1, HVR-H2, and HVR-H3 of the antibody CD-07 (as shown in Table 14) and the VL comprises the HVR-L1, HVR-L2, and HVR-L3 of the antibody CD-01 (as shown in Table 15);
- h. VH and VL, wherein the VH comprises the HVR-H1, HVR-H2, and HVR-H3 of the antibody CD-08 (as shown in Table 14) and the VL comprises the HVR-L1, HVR-L2, and HVR-L3 of the antibody CD-01 (as shown in Table 15);
- i. VH and VL, wherein the VH comprises the HVR-H1, HVR-H2, and HVR-H3 of the antibody CD-09 (as shown in Table 14) and the VL comprises the HVR-L1, HVR-L2, and HVR-L3 of the antibody CD-01 (as shown in Table 15);
- j. VH and VL, wherein the VH comprises the HVR-H1, HVR-H2, and HVR-H3 of the antibody CD-10 (as shown in Table 14) and the VL comprises the HVR-L1, HVR-L2, and HVR-L3 of the antibody CD-01 (as shown in Table 15);
- k. VH and VL, wherein the VH comprises the HVR-H1, HVR-H2, and HVR-H3 of the antibody CD-11 (as shown in Table 14) and the VL comprises the HVR-L1, HVR-L2, and HVR-L3 of the antibody CD-01 (as shown in Table 15);
- l. VH and VL, wherein the VH comprises the HVR-H1, HVR-H2, and HVR-H3 of the antibody CD-12 (as shown in Table 14) and the VL comprises the HVR-L1, HVR-L2, and HVR-L3 of the antibody CD-01 (as shown in Table 15);
- m. VH and VL, wherein the VH comprises the HVR-H1, HVR-H2, and HVR-H3 of the antibody CD-13 (as shown in Table 14) and the VL comprises the HVR-L1, HVR-L2, and HVR-L3 of the antibody CD-01 (as shown in Table 15);
- n. VH and VL, wherein the VH comprises the HVR-H1, HVR-H2, and HVR-H3 of the antibody CD-14 (as shown in Table 14) and the VL comprises the HVR-L1, HVR-L2, and HVR-L3 of the antibody CD-01 (as shown in Table 15);
- o. VH and VL, wherein the VH comprises the HVR-H1, HVR-H2, and HVR-H3 of the antibody CD-15 (as shown in Table 14) and the VL comprises the HVR-L1, HVR-L2, and HVR-L3 of the antibody CD-01 (as shown in Table 15);
- p. VH and VL, wherein the VH comprises the HVR-H1, HVR-H2, and HVR-H3 of the antibody CD-16 (as shown in Table 14) and the VL comprises the HVR-L1, HVR-L2, and HVR-L3 of the antibody CD-01 (as shown in Table 15);
- q. VH and VL, wherein the VH comprises the HVR-H1, HVR-H2, and HVR-H3 of the antibody CD-17 (as shown in Table 14) and the VL comprises the HVR-L1, HVR-L2, and HVR-L3 of the antibody CD-01 (as shown in Table 15);
- or
- r. VH and VL, wherein the VH comprises the HVR-H1, HVR-H2, and HVR-H3 of the antibody CD-18 (as shown in Table 14) and the VL comprises the HVR-L1, HVR-L2, and HVR-L3 of the antibody CD-01 (as shown in Table 15).
16 more elements
Dependencies are inferred from the claim text.